Chien-Hung Gow

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/528434/publications.pdf

Version: 2024-02-01

		687363	940533
17	537	13	16
papers	citations	h-index	g-index
17	17	17	910
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response. Clinical Cancer Research, 2008, 14, 162-168.	7.0	140
2	Positive end-expiratory pressure titration with electrical impedance tomography and pressure–volume curve in severe acute respiratory distress syndrome. Annals of Intensive Care, 2019, 9, 7.	4.6	64
3	Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C. Cancer Letters, 2017, 402, 190-202.	7.2	57
4	A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population. Lung Cancer, 2017, 103, 82-89.	2.0	47
5	Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer. International Journal of Cancer, 2019, 145, 1609-1624.	5.1	40
6	miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-κB Pathway. Molecular Therapy - Nucleic Acids, 2020, 22, 471-483.	5.1	28
7	Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer. Neoplasia, 2018, 20, 838-847.	5.3	25
8	Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case. Medical Oncology, 2014, 31, 34.	2.5	21
9	The Optimal Corepressor Function of Nuclear Receptor Corepressor (NCoR) for Peroxisome Proliferator-activated Receptor \hat{I}^3 Requires G Protein Pathway Suppressor 2. Journal of Biological Chemistry, 2015, 290, 3666-3679.	3.4	20
10	The incidence and interpretation of large differences in EIT-based measures for PEEP titration in ARDS patients. Journal of Clinical Monitoring and Computing, 2020, 34, 1005-1013.	1.6	19
11	Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas. Cancers, 2019, 11, 866.	3.7	18
12	Comparable clinical outcomes in patients with HER2â€mutant and EGFRâ€mutant lung adenocarcinomas. Genes Chromosomes and Cancer, 2017, 56, 373-381.	2.8	17
13	Regional air trapping in acute exacerbation of obstructive lung diseases measured with electrical impedance tomography: a feasibility study. Minerva Anestesiologica, 2020, 86, 172-180.	1.0	16
14	Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib. Journal of Thoracic Oncology, 2015, 10, e58-e60.	1.1	14
15	Clinicopathological Features and Survival Outcomes of Primary Pulmonary Invasive Mucinous Adenocarcinoma. Cancers, 2021, 13, 4103.	3.7	9
16	Determination of Low Muscle Mass by Muscle Surface Index of the First Lumbar Vertebra Using Low-Dose Computed Tomography. Journal of Clinical Medicine, 2022, 11, 2429.	2.4	2
17	Transcriptional and Genomic Control of Stem Cells in Development and Cancer. Stem Cells International, 2017, 2017, 1-2.	2.5	0